Drug development is slow, expensive, and often times the end result is a molecule that only works for a subpopulation of patients. Genetics are showing us that the most impactful drugs target the root cause of a disease, following the unique biology of a patient or acute patient population, but the pharma business model has no interest in scaling thousands of treatments for thousands of small diseases. If we don't change our way of thinking, it has been said it will take a thousand years to treat genetic disease, and billions of lives will be lost. AlphaRose can change that.

- Alpha Rose has raised 2.1m
The Company is co-founded by executives from the infamous Genzyme Corporation, and collectively has commercialized over 20 rare disease products globally.
- They in-licensed Rosiphersen which is slated for clinic in 2026, with an expected peak annual revenue of 700m.
- The AI platform they are developing has already identified 300+ diseases that are potentially amenable to their technology platform.
- AlphaRose has acquired a new ASO technology, giving it the ability to out license, and co-develop treatments.